Table 1.
Demographic and clinical characteristics of study participants
| Characteristics | Total | Stage I | Stage II | Stage III | Stage IV |
|---|---|---|---|---|---|
| Number of patients | N = 65 | N = 9 | N = 12 | N = 15 | N = 29 |
| Age at enrollment, years | |||||
| Median | 67 | 67 | 69 | 70 | 63 |
| Range | 36‐92 | 49‐79 | 46‐79 | 39‐83 | 36‐92 |
| Sex, n (%) | |||||
| Male | 39 (60%) | 6 (67%) | 7 (58%) | 10 (67%) | 16 (55%) |
| Female | 26 (40%) | 3 (33%) | 5 (42%) | 5 (33%) | 13 (45%) |
| Tissue gene status, n (%) | |||||
| KRAS‐MUT | 25 (38%) | 2 (22%) | 2 (17%) | 6 (40%) | 15 (52%) |
| BRAF‐MUT | 10 (15%) | 2 (22%) | 4 (33%) | 1 (7%) | 3 (10%) |
| WT | 18 (28%) | 2 (22%) | 4 (33%) | 5 (33%) | 7 (24%) |
| Unknown | 12 (18%) | 3 (33%) | 2 (17%) | 3 (20%) | 4 (14%) |
| CTC detection rate, n (%) | |||||
| Performed CTC analysis | 54 (83%) | 7 (78%) | 12 (100%) | 13 (87%) | 22 (76%) |
| Patients with CTCs | 29 (54%) | 4 (57%) | 7 (58%) | 8 (62%) | 10 (45%) |
| Patients without CTCs | 25 (46%) | 3 (43%) | 5 (42%) | 5 (38%) | 12 (55%) |
| CTC numbers | |||||
| Median | 1 | 1 | 2 | 1 | 0 |
| Range | 0‐8 | 0‐4 | 0‐8 | 0‐6 | 0‐5 |
| Not available | 11 | 2 | 0 | 2 | 7 |
KRAS‐MUT includes the G12D, G12V, G12C and G13D variants, whereas BRAF‐MUT refers to the V600E mutation.
Abbreviation: CTC, circulating tumor cells.